572 related articles for article (PubMed ID: 28338622)
1. Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair.
Knott EP; Assi M; Rao SN; Ghosh M; Pearse DD
Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28338622
[TBL] [Abstract][Full Text] [Related]
2. Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases.
Kokkonen K; Kass DA
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():455-479. PubMed ID: 27732797
[TBL] [Abstract][Full Text] [Related]
3. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
Cheng J; Grande JP
Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
[TBL] [Abstract][Full Text] [Related]
4. Advances in targeting cyclic nucleotide phosphodiesterases.
Maurice DH; Ke H; Ahmad F; Wang Y; Chung J; Manganiello VC
Nat Rev Drug Discov; 2014 Apr; 13(4):290-314. PubMed ID: 24687066
[TBL] [Abstract][Full Text] [Related]
5. Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway.
Eckly AE; Lugnier C
Br J Pharmacol; 1994 Oct; 113(2):445-50. PubMed ID: 7834194
[TBL] [Abstract][Full Text] [Related]
6. Effect of phosphodiesterase (1B, 2A, 9A and 10A) inhibitors on central nervous system cyclic nucleotide levels in rats and mice.
Chen J; Zook D; Crickard L; Tabatabaei A
Neurochem Int; 2019 Oct; 129():104471. PubMed ID: 31121256
[TBL] [Abstract][Full Text] [Related]
7. Cyclic Nucleotides Signaling and Phosphodiesterase Inhibition: Defying Alzheimer's Disease.
Sharma VK; Singh TG; Singh S
Curr Drug Targets; 2020; 21(13):1371-1384. PubMed ID: 32718286
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase in heart and vessels: from physiology to diseases.
Fu Q; Wang Y; Yan C; Xiang YK
Physiol Rev; 2024 Apr; 104(2):765-834. PubMed ID: 37971403
[TBL] [Abstract][Full Text] [Related]
9. Cardiac Cyclic Nucleotide Phosphodiesterases: Roles and Therapeutic Potential in Heart Failure.
Preedy MEJ
Cardiovasc Drugs Ther; 2020 Jun; 34(3):401-417. PubMed ID: 32172427
[TBL] [Abstract][Full Text] [Related]
10. The Construction and Application of a New Screening Method for Phosphodiesterase Inhibitors.
Gao C; Wang Z; Liu X; Sun R; Ma S; Ma Z; Wang Q; Li G; Zhang HT
Biosensors (Basel); 2024 May; 14(5):. PubMed ID: 38785726
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapeutic potential of phosphodiesterase inhibitors.
Perry MJ; Higgs GA
Curr Opin Chem Biol; 1998 Aug; 2(4):472-81. PubMed ID: 9736920
[TBL] [Abstract][Full Text] [Related]
12. Development of Phosphodiesterase-Protein-Kinase Complexes as Novel Targets for Discovery of Inhibitors with Enhanced Specificity.
Tulsian NK; Sin VJ; Koh HL; Anand GS
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34063491
[TBL] [Abstract][Full Text] [Related]
13. Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications.
Miller CL; Yan C
J Cardiovasc Transl Res; 2010 Oct; 3(5):507-15. PubMed ID: 20632220
[TBL] [Abstract][Full Text] [Related]
14. Clinical and molecular genetics of the phosphodiesterases (PDEs).
Azevedo MF; Faucz FR; Bimpaki E; Horvath A; Levy I; de Alexandre RB; Ahmad F; Manganiello V; Stratakis CA
Endocr Rev; 2014 Apr; 35(2):195-233. PubMed ID: 24311737
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease.
Xi M; Sun T; Chai S; Xie M; Chen S; Deng L; Du K; Shen R; Sun H
Eur J Med Chem; 2022 Mar; 232():114170. PubMed ID: 35144038
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase regulation of alcohol drinking in rodents.
Logrip ML
Alcohol; 2015 Dec; 49(8):795-802. PubMed ID: 26095589
[TBL] [Abstract][Full Text] [Related]
17. Targeting Phosphodiesterases in Pharmacotherapy for Substance Dependence.
Wen RT; Liang JH; Zhang HT
Adv Neurobiol; 2017; 17():413-444. PubMed ID: 28956341
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington's disease.
Cardinale A; Fusco FR
CNS Neurosci Ther; 2018 Apr; 24(4):319-328. PubMed ID: 29500937
[TBL] [Abstract][Full Text] [Related]
19. Cyclic nucleotide phosphodiesterases: New targets in the metabolic syndrome?
Lugnier C; Meyer A; Talha S; Geny B
Pharmacol Ther; 2020 Apr; 208():107475. PubMed ID: 31926200
[TBL] [Abstract][Full Text] [Related]
20. Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 1: Overview of the Chemical and Biological Research.
Jankowska A; Świerczek A; Wyska E; Gawalska A; Bucki A; Pawłowski M; Chłoń-Rzepa G
Curr Drug Targets; 2019; 20(1):122-143. PubMed ID: 30091414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]